Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Malignancy
Questions discussed in this category
Do you continue methotrexate in patients with inflammatory arthritis who develop non-melanomatous skin cancer while on therapy?
1 Answer available
How do you counsel patients about the malignancy risk associated with azathioprine?
1 Answer available
How do you approach evaluation of hypocomplementemia in a patient with arthralgias and a history of Hodgkin's lymphoma treated in the past?
ANA and ENA negative
1 Answer available
How do you manage dermatomyositis related to underlying malignancy?
Is there a role of immunosuppression or treating underlying malignancy will be enough?
1 Answer available
Does discovery of clonal hematopoiesis on liquid biopsy for solid tumors change your treatment approach in terms of which chemotherapy to offer for the solid tumor?
1 Answer available
Would you continue TNFi for inflammatory arthritis if the patient develops a solid organ malignancy while on that therapy?
1 Answer available
How do you approach treatment of rheumatoid arthritis in a patient with an active hematologic malignancy (such as leukemia or lymphoma) after methotrexate failure?
Does your management change if there is renal involvement of the malignancy?
2 Answers available
How would you treat uveitis in a patient with a history of cutaneous T cell lymphoma?
Patient was previously well controlled on methotrexate, which was discontinued during cancer treatment.
1 Answer available
9495
15365
15387
14191
11096
8040
9127
8910
Papers discussed in this category
British journal of cancer, 2023 Feb 04
Use of methotrexate and risk of skin cancer: a nationwide case-control study.
Related Topics
Rheumatology
General Rheumatology
Internal Medicine
Hematologic Malignancies
Rheumatoid Arthritis
Myositis
Hematology
Medical Oncology
Dermatomyositis
Cancer